Latest News

Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, discusses the clinical significance of the phase 3 PROTEUS trial and addresses concerns about the study's use of ADT in the control arm.

Amy Pearlman, MD, and Larry I. Lipshultz, MD, speak with Shane Kronstedt, MD, about research on the long-term reproductive and urologic effects of military exposures and how these findings may help improve care for veterans.

Experts discuss why CIS is frequently underrecognized, highlighting the subtle clinical and cystoscopic features of the disease and the importance of integrating multiple factors to improve detection.

This marks the first phase 3 study of a targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.

Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG‒naïve NMIBC.

Results from a first-in-human phase 0 feasibility trial showed that combined bladder and kidney transplantation was technically feasible.

Kathryn H. Gessner, MD, PhD, discusses the current limitations in identifying appropriate candidates for bladder-preserving trimodal therapy, the promise of utDNA, and why shared decision-making remains essential.

A secondary analysis of the ASPIRE trial found residual stone volume—not conventional stone-free status, baseline volume, or density—is the strongest predictor of post-ureteroscopy health care utilization, with each 100-mm³ increase doubling event odds.

The Department of Defense will begin annual testosterone deficiency screening for service members aged 30 years and older.

Jamie Michael, MD, highlights a study exploring the impact of MRI and genomics on "extreme" grade reclassification in men on active surveillance.

Dose interruption rather than discontinuation addresses most gemcitabine intravesical system (Inlexzo) adverse events, with designated champions supporting consistent patient management, according to Elizabeth Mobley, MD.

Elizabeth Mobley, MD, shares practical tips for counseling patients and managing adverse events during treatment with the gemcitabine intravesical system.

Proactive adverse event counseling and a specific hydration protocol are the primary tools for supporting patient retention through the gemcitabine intravesical system's (Inlexzo) extended treatment course, according to Mobley.